Impact of the background regimen on virologic response to etravirine: Pooled 48-week analysis of DUET-1 and-2

HIV Clinical Trials

Volumn 11, Issue 4, 2010, Pages 175-185

  Trottier, Benoit ^a   Di Perri, Giovanni ^b   Madruga, José ^c   Peeters, Monika ^d   Vingerhoets, Johan ^d   Picchio, Gaston ^e   Woodfall, Brian ^d  

^a Clinique Medicale l'Actuel   (Canada)

^b UNIVERSITY OF TURIN   (Italy)

^c Centro de Referencia e Treinamento DST/AIDS   (Brazil)

^d TIBOTEC BVBA   (Belgium)

^e Tibotec Inc   (United States)

Author keywords

background regimen; DUET; efficacy; etravirine; HIV 1; TMC125; treatment experienced

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; PLACEBO; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 78049438484     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1104-175     Document Type: Article

References (40)

1. US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. http://www. aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf Accessed January 8, 2010.
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. J Am Med Assoc. 2010;304:321-333.
3. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
4. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65-71.
5. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse tran-scriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-4686.
6. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773-12782.
7. Madruga J V, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
8. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
9. Katlama C, Haubrich R, Lalezari J, et al. efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled week 48 analysis of two randomized, controlled trials. AIDS. 2009;23:2289-2300.
10. Katlama C, Clotet B, Mills A, et al. efficacy and safety of etravirine at Week 96 in treatment-experienced HIV-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. In press.
11. TM (etravirine) prescribing information. August 2009. www.intelence-info.com/intelence/assets/pdf/INTELENCE-PI.pdf. Accessed September 29, 2009.
12. INTELENCE (etravirine): summary of product characteristics (EMEA). www.emea.europa.eu/humandocs/Humans/EPAR/intelence/intelence.htm. Accessed September 29. 2009.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005;13:125-131.
14. Tambuyzer L, Vingerhoets J, Azijn H, et al. Development of a list of mutations associated with NNRTI resistance for use in clinical research. Presented at: 5th European HIV Drug Resistance Workshop; March 28-30, 2007; Cascais, Portugal. Abstract 67.
15. De Meyer S, Dierynck I, Lathouwers E, et al. Identifi cation of mutations predictive of a diminished response to darunavir/ritonavir: analysis of data from treatment-experienced patients in POWER 1,2,3 and DUET-1 and DUET-2. Presented at: 6th European HIV Drug Resistance Workshop; March 26-28, 2008; Budapest, Hungary. Abstract 54.
16. Lapadula G, Calabresi A, Castelnuovo F, et al. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2008;13:601-605.
17. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS. 2008;22:989-990.
18. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating the role of etra-virine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res. 2008;6:474-476.
19. Picchio G, Vingerhoets J, Staes M, et al. Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts. Abstract 866.
20. Clotet B, Bellos N, Molina JM, et al. efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
21. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.
22. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus Optimized background Regimen Only 1 and 2 clinical trials. J Acquir Immune Defi c Syndr. 2005;40:404-412.
23. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-475.
24. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442-1455.
25. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profi le of etravirine: combined analysis of baseline geno-typic and phenotypic data from the DUET studies. AIDS. 2010;24:503-514.
26. Clumeck N, Clotet B, Johnson M, Peeters M, Vinger-hoets J, Beets G, De Smedt G. Virological response with fully active etravirine after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials. Presented at: 9th International Congress on Drug Therapy in HIV Infection; November 9-13, 2008; Glasgow, UK. Abstract P023.
27. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49:1441-1449.
28. Nozza S, Visco F, Soria A, et al. Excellent short-term CD4 recovery with a PI-and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine. Presented at: 9th International Congress on Drug Therapy in HIV Infection; November 9-13, 2008; Glasgow, UK. Abstract P45.
29. Towner W, Lalezari J, Sension MG, et al. efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. AIDS. 2010;53:614-618.
30. Anderson MS, Kakuda TN, Hanley W, et al. Minimal phar-macokinetic interaction between the HIV non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52:4228-4232.
31. Davis J, Schöller-Gyüre M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etra-virine) and the combination of TMC125/darunavir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects. Presented at: 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract P4.3/02.
32. Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharma-cokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-796.
33. Kakuda TN, Schöller-Gyüre M, Hoetelmans RMW. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etra-virine. Antivir Ther. In press.
34. Schöller-Gyüre M, Woodfall B, Bollen S, Peeters M, Vandermeulen K, Hoetelmans R. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir. Presented at: 46th Interscience Conference on Antimicrobial Agents andChemotherapy; September 27-30 2006; San Francisco, California, USA. Abstract A-370.
35. Kakuda TN, Schöller-Gyüre M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2009;10:173-181.
36. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
37. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-F18.
38. Schöller M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado, USA. Abstract 583.
39. Schapiro J, Vingerhoets J, Nijs S, et al. Combined protease inhibitor (PI) and NNRTI resistance analysis of the pooled DUET trial: towards a regimen-based resistance interpretation. Presented at: 6th European HIV Drug Resistance Workshop; March 26-28, 2008; Budapest, Hungary. Abstract 46.
40. Haubrich R, Schapiro J, Vingerhoets J, et al. Combined darunavir and etravirine resistance analysis of the pooled DUET trials: when can we spare the other new classes? Presented at: 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico. Abstract TUPE0048.